NEW YORK (TheStreet) -- Omeros(OMER) - Get Report shares are up 72.58% to $25.17 in mid-morning trading on Tuesday, after the Seattle, WA-based biopharmaceutical company reported additional positive data from the phase 2 study of its thrombotic microangiopathies (TMA) treatment candidate.
TMAs are a rare family of life-threatening clotting disorders and OMS721 is the company's lead human monoclonal antibody treatment candidate.
"We are excited by the data from this Phase 2 clinical trial with OMS721, both with respect to aHUS and TTP patients," CEO Gregory A. Demopulos M.D. said in a statement.
TMAs are characterized by clumps of aggregated platelets in small blood vessels which leads to below-normal platelet counts and the fragmentation of red blood cells.
The company reported that in the mid-dose cohort, two patients demonstrated a 47% increase in mean platelet count and an 86% decrease in red blood cell fragmentation.